Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 17,845 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Portal Hypertension, Liver Cirrhosis
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more

Conditions: Pancreatic Cancer
Interventions: MeIQx, Pancreatectomy; Radiation · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo matching BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 1,755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: COPD, Interstitial Lung Disease
Interventions: MoblO2 control; Device
Lead sponsor: National Jewish Health; Other
Eligibility: 25 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Musculoskeletal Complications
Interventions: levocarnitine, placebo, questionnaire administration; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions: Oral Ifetroban, Oral Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more

Conditions: Melanoma
Interventions: POL-103A, POL-103A without API; Biological
Lead sponsor: Polynoma LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 59
States / cities: Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 50 more

Conditions: Gynecologic Cancer, Endometrial Cancer, Cervical Cancer, Quality of Life, Opioid Use
Interventions: Headspace Smartphone Application; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sleep Apnea, Sleep Disturbance
Interventions: Couples-based treatment- Patient, Couples-based treatment- Partner, Information control- Patient, Information control- Partner; Behavioral · Other
Lead sponsor: University of Utah; Other
Eligibility: 35 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Tuscon, Arizona • Salt Lake City, Utah

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: Bone Graft, Tooth Extraction
Interventions: Dexamethasone 4mg/ml solution; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Meniscal Tear, Chondromalacia
Interventions: Arthroscopic debridement; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 30 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: vildagliptin, sitagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Placebo, Serostim® 4 mg, Serostim® 2 mg; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more

Conditions: Systemic Lupus Erythematosus
Interventions: GDC-0853, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Alamitos, California • Boca Raton, Florida + 15 more

Conditions: Head and Neck Cancer, Taste Dysfunction
Interventions: Miraculin, Miracle Fruit Placebo Cube; Drug · Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions: Point-of-care STI tests, Standard of care STI testing; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: Female only
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hyponatremia
Interventions: YM087; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Tuscon, Arizona + 24 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Peoria, Arizona • Newport Beach, California • Sacramento, California + 12 more

Conditions: Alopecia Areata
Interventions: CTP-543, CTP-543 matching placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Irvine, California • Rancho Mirage, California • Redwood City, California + 10 more

Conditions: Tracheoesophageal Fistula, Esophageal Atresia, Laryngeal Cleft, Tracheal Stenosis, Bronchial Stenosis, Esophageal Bronchus, Congenital High Airway Obstruction Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiac Output
Interventions: supine position, 15 degrees lateral tilt, 30 degrees lateral tilt; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Atrial Flutter
Interventions: Blazer® Open-Irrigated Ablation Catheter, Control Catheter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Fullerton, California • Sacramento, California + 21 more

Search by objective public record fields.

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

MOBoxy: MoblO2 to Maintain Oxygenation

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Mindfulness in Endometrial and Cervical Cancer

Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline

The ChAMP (Chondral Lesions And Meniscus Procedures) Trial

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Improving Maternal and Child Health Through Point-of-care STI Testing

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients

Assessing Effects of Lateral Tilt on Cardiac Output Using a Non-invasive Technique

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter